Experiment 635086
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | SAUDREAU,F: SERISE,JM: PILLET,J: MAIZA,D: MERCIER,V: KRETZ,JG: THIBERT,A:. (1989). EFFICIENCY OF GINKGO-BILOBA EXTRACT IN TREATMENT OF STAGE III (FONTAINE CLASSIFICATION) CHRONIC OCCLUSIVE AERTERIAL DISEASES OF THE LOWER LIMBS.. 14() |
| Amount utilized | |
| Compound isolated | |
| Disease | A CONTROLLED TRIAL OF GINKGO-BILOBA EXTRACT IN INJECTABLE FORM (TANAKA 50 MG, A LYOPHILISATE FOR PARENTERAL USE) WAS CARRED OUT VERSUS A PLACEBO AS PREOPERATIVE MEDICAL TREATMENT OF STAGE III (FONTAINE CLASSIFICAITON) CHRONIC OCCLUSIVE ARTERIAL DISEASES OF THE LOWER LIMBS (WITH PAIN IN DECUBITUS). THE 64 MEN AND WOMEN PATIENTS IN THIS MULTICENTER STUDY (32 IN EACH GROUP) WERE OVER 18 YEARS OF AGE AND HAD A CULTURAL AND INTELLECTURAL LEVEL AS WELL AS A PHYSICLA CONDITION ALLOWING THEM TO PLAY AN ACTIVE ROLE IN THE EXPERIMENT (SELF-EVALUAITON OF PAIN). DURING 8 DAYS THEY RECEIVED TWO DAILY INFUSIONS OF 500 CC OF NORMAL SALINE SOLUTION CONTAINING EITHER 100 MG OF GINKGO-BILOBA EXTRACT ORO A PLACEBO OF IDENTICAL APPEARANCE. PAIN RATED ACCORDING TO A VISUAL SCALE, WITH EACH PATIENT MAKING A POINT BETWEEN TWO EXTREMES (<<MAXIMUM IMAGINABLE PAIN>> AND << TOTAL ABSENCE OF PAIN>>) 100 MM APART. THE TWO RANDOMLY-COMPOSED GROUPS WITH GINKGO-BILOBA EXTRACT AND A PLACEBO WERE COMPARABLE. ANALYSIS WAS BASED ON 55 OBSERVATIONS (26 IN THE EXTRACT GROUP AND 29 IN THE PLACEBO GROUP). COMPARISON OF THE GROUPS SHOWED A STATISTICALLY SIGNIFICANT SUPERIORITY (P =0.04) OF THE EXTRACT. A COMMERCIAL PRODUCT, TANAKAN, WAS USED. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | LYOPHILIZED EXTRACT |
| Gender | GIVEN TO BOTH SEXES |